State of Play

armed forces covenant

Transforming Lives:
Why British Veterans Need Assisted Psychotherapy

The Armed Forces Covenant promises that no veteran shall face disadvantage for their service, yet current PTSD treatments leave too many British veterans struggling without effective care.

Britain’s veterans are facing a silent crisis that fractures families, communities, and lives. A two-decade King’s College London study found one in three veterans suffer from common mental disorders, PTSD, or alcohol misuse with the vast majority of those with PTSD having symptoms of Complex PTSD, a chronic condition that affects emotional regulation and is significantly harder to treat (1).

UK service leavers face “significant and complex comorbid mental health and wellbeing difficulties, including depression, anxiety, addictions, homelessness, social exclusion, and unemployment.” (2). Journal-veterans-studies Male veterans aged 25 to 44 have a much higher rate of suicide compared to the same age group in the general population, 38.2 deaths per 100,000 compared to 18 per 100,000 for civilians (3).

On average, it takes veterans 4 years from leaving the Armed Forces to seek mental health support and successful implementation of treatments is challenged because veterans are described as unstable, unreliable and hard to engage due to inherent difficulties with help-seeking (4) (5) (6).

Assisted psychotherapy represents a paradigm shift that addresses these barriers directly. MDMA can reduce PTSD symptoms even in treatment-resistant cases by facilitating emotional breakthroughs and enhancing the therapeutic process, offering profound benefits for those who have failed conventional treatments (7).

Following treatment, 54.2% of participants no longer met diagnostic scores for PTSD compared to only 22.6% in control groups. King’s College London’s Psychoactive Trials Group is undertaking controlled clinical trials with MDMA for PTSD, positioning the UK at the forefront of this therapeutic revolution (8) (9).

In 2022, MAPS was granted an Innovation Passport for MDMA-assisted therapy for PTSD in the UK, signalling regulatory recognition of its potential (10). For veterans trapped in cycles of trauma, failed treatments, and social isolation, assisted psychotherapy offers genuine hope for recovery, reconnection with families, and meaningful participation in society.